Mebendazole and TP53

Why mebendazole appears less dependent on intact p53 than fenbendazole, and how TP53 status still shapes interpretation

Does mebendazole still make sense if the tumour has a TP53 mutation?

The short answer is yes, often more than fenbendazole does.

Mebendazole does not appear to need intact p53 for its core anticancer activity.

That is the key difference from Fenbendazole and TP53, where the best-known anticancer mechanism seems to rely more on p53-driven cell death.

For the wider mechanism set, see Mebendazole Anticancer Mechanisms.

What this means in practice

A TP53 mutation does not automatically rule out mebendazole.

The same is true if the tumour is p53-null, meaning it has lost usable p53.

TP53 still matters because it can change how the drug stresses the cancer cell.

If p53 is present, mebendazole may use some p53-linked signals.

If p53 is mutated or missing, it can still work through other routes.

What the evidence shows

1. Ovarian-cancer models

In ovarian-cancer models with wild-type, mutant, and null p53, mebendazole inhibited growth and induced apoptosis across all three settings.

That study also supported p53-independent p21 induction alongside microtubule depolymerisation.

2. Lung-cancer models

In some lung-cancer models, mebendazole increased p53, p21, and MDM2.

In p53-null cells, it still triggered:

cytochrome-c release
caspase activation
PARP cleavage

That means it could still drive apoptosis without needing p53.

3. Diffuse midline glioma models

In diffuse midline glioma models, mebendazole caused G2/M arrest and apoptosis across different TP53 backgrounds.

Some models also showed p53 phosphorylation or upregulation.

So p53 can be involved when it is present, but the drug does not appear to depend on it.

How this differs from fenbendazole

Fenbendazole looks more tied to p53-driven cell death.

Mebendazole looks broader.

Its effects have been reported in tumours with wild-type, mutant, and null p53.

How to interpret this in practice

If you are reading a tumour report:

TP53 mutation or loss is not a clear disqualifier.
Somatic TP53 still helps explain the biology.
Tumour type still matters more than gene status alone.

If you are trying to decode the report itself, start with Somatic TP53 and the wider TP53 in Cancer Overview.

Key references

Mebendazole as a Candidate for Drug Repurposing in Oncology
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/

Mebendazole induces apoptosis by targeting ABCB1 and p53-independent p21 in ovarian cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC8820236/

Anti-tumor effect of mebendazole in diffuse midline glioma cells with H3K27M mutation
https://e-century.us/files/ajcr/15/6/ajcr0163760.pdf

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.